Patents by Inventor Andrew Reaume

Andrew Reaume has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170173004
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
    Type: Application
    Filed: August 8, 2016
    Publication date: June 22, 2017
    Inventors: Andrew Reaume, Heather Hain, Michael S. Saporito
  • Patent number: 9408844
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: August 9, 2016
    Assignee: Melior Discovery, Inc.
    Inventors: Andrew Reaume, Heather Hain, Michael S. Saporito
  • Publication number: 20140227209
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: Melior Discovery, Inc.
    Inventors: Andrew Reaume, Heather Hain, Michael S. Saporito
  • Patent number: 8716294
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: May 6, 2014
    Assignee: Melior Discovery, Inc.
    Inventors: Andrew Reaume, Heather Hain, Michael Saporito
  • Patent number: 8343985
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: January 1, 2013
    Assignee: Melior Pharmaceuticals I, Inc.
    Inventors: Andrew Reaume, Michael S. Saporito
  • Publication number: 20100278804
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Application
    Filed: July 15, 2010
    Publication date: November 4, 2010
    Applicant: MELIOR PHARMACEUTICALS I, INC.
    Inventors: Andrew Reaume, Michael S. Saporito
  • Patent number: 7776870
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: August 17, 2010
    Assignee: Melior Pharmaceuticals I, Inc.
    Inventors: Andrew Reaume, Michael S. Saporito
  • Publication number: 20100152215
    Abstract: The present invention relates to methods of identifying activators of lyn kinase by preincubating a test compound in the presence of lyn kinase; adding ATP and substrate to the lyn kinase and test compound; incubating the test compound, lyn kinase, ATP, and substrate; and measuring phosphorylation level of the substrate, whereby an increase in the phosphorylation of the substrate indicates that the test compound is an activator of lyn kinase.
    Type: Application
    Filed: February 20, 2008
    Publication date: June 17, 2010
    Applicant: MELIOR PHARMACEUTICALS I, INC.
    Inventors: Andrew Reaume, Michael Saporito
  • Publication number: 20080161319
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.
    Type: Application
    Filed: November 9, 2007
    Publication date: July 3, 2008
    Applicant: MELIOR DISCOVERY, INC.
    Inventors: Andrew Reaume, Heather Hain, Michael Saporito
  • Publication number: 20070105878
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salt thereof that are useful for treating or preventing depression; multiple sclerosis; irritable bowel syndrome; low compliance bladder; urinary incontinence; constipation; gastrointestinal pain; and related disorders.
    Type: Application
    Filed: October 3, 2006
    Publication date: May 10, 2007
    Inventors: Andrew Reaume, Michael Saporito
  • Publication number: 20070093516
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Application
    Filed: August 22, 2006
    Publication date: April 26, 2007
    Inventors: Andrew Reaume, Michael Saporito